Dendritic Cell Vaccines for Cancer Immunotherapy

• John M. Timmerman, MD

  Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, California 94305;

• Ronald Levy, MD

  Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, California 94305;

抄録

Human tumors express a number of protein antigens that can be recognized by T cells, thus providing potential targets for cancer immunotherapy. Dendritic cells (DCs) are rare leukocytes that are uniquely potent in their ability to present antigens to T cells, and this property has prompted their recent application to therapeutic cancer vaccines. Isolated DCs loaded with tumor antigen ex vivo and administered as a cellular vaccine have been found to induce protective and therapeutic anti-tumor immunity in experimental animals. In pilot clinical trials of DC vaccination for patients with non-Hodgkin's lymphoma and melanoma, induction of anti-tumor immune responses and tumor regressions have been observed. Additional trials of DC vaccination for a variety of human cancers are under way, and methods for targeting tumor antigens to DCs in vivo are also being explored. Exploitation of the antigen-presenting properties of DCs thus offers promise for the development of effective cancer immunotherapies.

収録刊行物

• Annual Review of Medicine

  Annual Review of Medicine 50 (1), 507-529, 1999-02

  Annual Reviews

キーワード

• General Biochemistry, Genetics and Molecular Biology
• General Medicine

詳細情報

• CRID: 1360011145297197056
• NII論文ID: 30022132686
• DOI: 10.1146/annurev.med.50.1.507
• ISSN: 1545326X
• ISSN: 00664219
• Web Site: https://www.annualreviews.org/doi/pdf/10.1146/annurev.med.50.1.507
• データソース種別:
  • Crossref
  • CiNii Articles